158 related articles for article (PubMed ID: 36423588)
1. Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.
Nester C; Appel GB; Bomback AS; Bouman KP; Cook HT; Daina E; Dixon BP; Rice K; Najafian N; Hui J; Podos SD; Langman CB; Lightstone L; Parikh SV; Pickering MC; Sperati CJ; Trachtman H; Tumlin J; de Vries AP; Wetzels JFM; Remuzzi G
Am J Nephrol; 2022; 53(10):687-700. PubMed ID: 36423588
[TBL] [Abstract][Full Text] [Related]
2. Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
Podos SD; Trachtman H; Appel GB; Bomback AS; Dixon BP; Wetzels JFM; Cook HT; Parikh SV; Pickering MC; Tumlin J; Langman CB; Lightstone L; Sperati CJ; Daina E; Bouman KP; Rice K; Thanassi JA; Huang M; Nester C; Remuzzi G
Am J Nephrol; 2022; 53(10):675-686. PubMed ID: 36404708
[TBL] [Abstract][Full Text] [Related]
3. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
[TBL] [Abstract][Full Text] [Related]
4.
Piras R; Breno M; Valoti E; Alberti M; Iatropoulos P; Mele C; Bresin E; Donadelli R; Cuccarolo P; Smith RJH; Benigni A; Remuzzi G; Noris M
Front Genet; 2021; 12():670727. PubMed ID: 34211499
[TBL] [Abstract][Full Text] [Related]
5. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
7. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
Front Immunol; 2021; 12():715704. PubMed ID: 34456924
[TBL] [Abstract][Full Text] [Related]
8. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
[TBL] [Abstract][Full Text] [Related]
9. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment.
Noris M; Daina E; Remuzzi G
Nephrol Dial Transplant; 2023 Feb; 38(2):283-290. PubMed ID: 34596686
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and Prognostic Comparison of Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.
Kovala M; Seppälä M; Räisänen-Sokolowski A; Meri S; Honkanen E; Kaartinen K
Cells; 2023 Feb; 12(5):. PubMed ID: 36899849
[TBL] [Abstract][Full Text] [Related]
12. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
[TBL] [Abstract][Full Text] [Related]
13. Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.
Bomback AS; Kavanagh D; Vivarelli M; Meier M; Wang Y; Webb NJA; Trapani AJ; Smith RJH
Kidney Int Rep; 2022 Oct; 7(10):2150-2159. PubMed ID: 36217526
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children.
Kirpalani A; Jawa N; Smoyer WE; Licht C;
Kidney Int Rep; 2020 Dec; 5(12):2313-2324. PubMed ID: 33305125
[TBL] [Abstract][Full Text] [Related]
15. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
[TBL] [Abstract][Full Text] [Related]
16. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis.
Gupta N; Wakefield DN; Clapp WL; Garin EH
Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516
[TBL] [Abstract][Full Text] [Related]
17. FHR-5 Serum Levels and
Garam N; Cserhalmi M; Prohászka Z; Szilágyi Á; Veszeli N; Szabó E; Uzonyi B; Iliás A; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Rysava R; Reiterova J; Saraga M; Seeman T; Zieg J; Sládková E; Stajic N; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Józsi M; Csuka D
Front Immunol; 2021; 12():720183. PubMed ID: 34566977
[TBL] [Abstract][Full Text] [Related]
18. [Membranoproliferative glomerulonephritis and C3 glomerulopathy].
Hohenstein B; Amann K; Menne J
Internist (Berl); 2019 May; 60(5):458-467. PubMed ID: 30859280
[TBL] [Abstract][Full Text] [Related]
19. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
Aradottir SS; Kristoffersson AC; Roumenina LT; Bjerre A; Kashioulis P; Palsson R; Karpman D
Front Immunol; 2021; 12():690821. PubMed ID: 34177949
[TBL] [Abstract][Full Text] [Related]
20. C3 Glomerulopathy.
Riedl M; Thorner P; Licht C
Pediatr Nephrol; 2017 Jan; 32(1):43-57. PubMed ID: 27056062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
